Pri-Med East

Boston, MA | December 4-7, 2019

Boston Convention & Exhibition Center

Going with the Flow: New Considerations in Type 2 Diabetes Management for Patients with Chronic Kidney Disease


Soon diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. Data suggest that the excess risk related to all-cause and cardiovascular mortality is concentrated among the those with T2DM and kidney disease. SGLT2 inhibitors have shown particular cardiovascular and renoprotective benefits. In this session, faculty will explain current data on the renoprotective properties of SGLT2 inhibitors and review guideline recommendations for using them in patients with type 2 diabetes and kidney disease. The practical cases throughout the lecture will train you to develop treatment plans for your patients with those comorbid diseases and enhance individualized care in your practice.

Learning Objectives

Explain current data surrounding the renoprotective properties of SGLT2 inhibitors

Review current guideline recommendations for using SGLT2 inhibitors in patients with T2DM and kidney disease

Develop individualized treatment plans for patients with T2DM and kidney disease


Charles Vega, MD, FAAFP

Chuck grew up in Northern California and completed his undergraduate degree at Harvard University. He attended medical school at the University of Wisconsin - Madison and completed residency training in family medicine at UC Irvine. He stayed on as f...

View Full Bio

Melanie Hoenig, MD

Melanie Hoenig, MD is a nephrologist at BIDMC. She has been the course director for Renal pathophysiology at Harvard Medical School for more than a dozen years. She served as a co-chair for the recent curriculum reform at Harvard Medical School and i...

View Full Bio

Educational Partners

Commercial Supporters

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC